Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Phase 4

Conditions: Colorectal Cancer

Interventions: Drug: tac + folfox4
Drug: folfox4

First Posted Date: 2009-04-02

Last Posted Date: 2009-04-02

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT00874406

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 12 cycles of oxaliplatine based adjuvant chemotherapy
Drug: 8 cycles of oxaliplatine based adjuvant chemotherapy

First Posted Date: 2009-03-25

Last Posted Date: 2009-03-25

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT00868816

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer

Phase 4

Completed

Conditions: Unresectable Liver Metastasis of Colorectal Cancer

Interventions: Procedure: Folfox4
Procedure: tac + folfox4

First Posted Date: 2009-03-25

Last Posted Date: 2009-03-25

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT00869271

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer

Phase 4

Conditions: Liver Metastasis
Colorectal Cancer

Interventions: Procedure: TACE + folfox 4
Procedure: TAC + folfox4

First Posted Date: 2009-03-25

Last Posted Date: 2009-03-25

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT00868569

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: CEOP regimen
Drug: CHOP regimen

First Posted Date: 2009-03-03

Last Posted Date: 2014-08-20

Lead Sponsor: Fudan University

Target Recruit Count: 398

Registration Number: NCT00854568

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: L-asparaginase

First Posted Date: 2009-03-03

Last Posted Date: 2012-02-20

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT00854425

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Radiation Dose Escalation Study for Advanced Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: 3DCRT/IMRT

First Posted Date: 2009-02-20

Last Posted Date: 2009-02-20

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT00848094

Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer

Phase 1

Conditions: Local Advanced Non-Small Cell Lung Cancer

Interventions: Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy

First Posted Date: 2009-02-18

Last Posted Date: 2009-02-18

Lead Sponsor: Fudan University

Target Recruit Count: 12

Registration Number: NCT00846443

Locations: 🇨🇳
Department of Radiation Oncolory, Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)

Phase 2

Conditions: T-Cell Lymphomas
Chemotherapy

Interventions: Drug: FAD

First Posted Date: 2009-02-10

Last Posted Date: 2010-09-15

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT00840385

Locations: 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Phase 2

Conditions: Colorectal Neoplasms

Interventions: Drug: sorafenib
Drug: FOLFIRI

First Posted Date: 2009-02-09

Last Posted Date: 2010-09-15

Lead Sponsor: Fudan University

Target Recruit Count: 43

Registration Number: NCT00839111

Locations: 🇨🇳
Cancer Hospital,Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy